Get the Stockscreener App
10.03
5.73%
-0.61
Kalvista Pharmaceuticals Inc stock is traded at $10.03, with a volume of 446.18K.
It is down -5.73% in the last 24 hours and up +14.63% over the past month.
KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. The company is also conducting preclinical development on a novel, oral, Factor XIIa inhibitor program.
See More
Previous Close:
$10.64
Open:
$10.85
24h Volume:
446.18K
Relative Volume:
1.24
Market Cap:
$495.66M
Revenue:
-
Net Income/Loss:
$-156.39M
P/E Ratio:
-2.7182
EPS:
-3.69
Net Cash Flow:
$-123.06M
1W Performance:
+2.77%
1M Performance:
+14.63%
6M Performance:
-20.27%
1Y Performance:
-23.08%
1-Day Range:
$9.975
$10.85
1-Week Range:
$9.63
$11.00
52-Week Range:
$7.30
$15.50
Kalvista Pharmaceuticals Inc Stock (KALV) Company Profile
Name
Kalvista Pharmaceuticals Inc
Sector
Industry
Phone
(857) 999-0075
Address
55 CAMBRIDGE PARKWAY, CAMBRIDGE, MA
Compare KALV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KALV
Kalvista Pharmaceuticals Inc
|
10.03 | 495.66M | 0 | -156.39M | -123.06M | -3.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Kalvista Pharmaceuticals Inc Stock (KALV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-31-25 | Initiated | JMP Securities | Mkt Outperform |
| Jan-07-25 | Initiated | TD Cowen | Buy |
| Dec-18-24 | Initiated | BofA Securities | Buy |
| Jun-15-20 | Initiated | H.C. Wainwright | Buy |
| Jul-29-19 | Initiated | SVB Leerink | Outperform |
| Mar-20-19 | Initiated | Needham | Buy |
| Oct-30-18 | Initiated | Jefferies | Buy |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-31-17 | Initiated | BTIG Research | Buy |
View All
Kalvista Pharmaceuticals Inc Stock (KALV) Latest News
Can This New Oral Drug Transform HAE Treatment? Key Clinical Data Revealed - StockTitan
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Benjamin L. Palleiko Sells 5,104 Shares - MarketBeat
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Insider Paul K. Audhya Sells 3,125 Shares - MarketBeat
KalVista Pharmaceuticals (NASDAQ:KALV) Trading Up 8.7%What's Next? - MarketBeat
KalVista Pharmaceuticals chief medical officer sells $30,700 in stock By Investing.com - Investing.com Canada
KalVista Pharmaceuticals CEO sells $50,142 in stock - Investing.com India
KalVista Pharmaceuticals chief medical officer sells $30,700 in stock - Investing.com India
KalVista Pharmaceuticals chief development officer sells shares for $25,552 - Investing.com India
KalVista Pharmaceuticals CEO sells $50,142 in stock By Investing.com - Investing.com Nigeria
KalVista Pharmaceuticals chief development officer sells shares for $25,552 By Investing.com - Investing.com Nigeria
KalVista Pharmaceuticals Executives Sell Shares for Tax Obligations - TradingView
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Short Interest Update - Defense World
Japan grants orphan drug status to HAE treatment - MSN
Venrock Healthcare Capital Par Purchases 100,000 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Stock - MarketBeat
(KALV) Investment Analysis - Stock Traders Daily
KalVista Pharmaceuticals sees $1.5m stock purchase by Venrock - MSN
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Major Shareholder Acquires $37,812.18 in Stock - MarketBeat
KalVista Pharmaceuticals sees $967,144 in stock purchases by Venrock - MSN
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Major Shareholder Venrock Healthcare Capital Par Purchases 73,649 Shares of Stock - MarketBeat
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Shares Bought by SG Americas Securities LLC - Defense World
Hereditary Angioedema Market Expected to rise, 2034 | KalVista - openPR
KalVista Completes Study On Hereditary Disorder Treatment: Shares Dip - BW Healthcare World
KalVista Pharmaceuticals Presents New Sebetralstat Data at the Western Society of Allergy, Asthma & Immunology 2025 Annual Meeting - The Bakersfield Californian
KALV: Sebetralstat Shows 1.3-Hour Relief in HAE Attacks, New Clinical Data Reveals | KALV Stock News - StockTitan
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Major Shareholder Venrock Healthcare Capital Par Purchases 43,707 Shares - MarketBeat
Insider Buying: KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Major Shareholder Purchases 14,562 Shares of Stock - MarketBeat
(KALV) Investment Report - Stock Traders Daily
JMP reiterates Kalvista stock with $19 target, sees market growth - MSN
Brokerages Set KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Target Price at $25.00 - MarketBeat
KalVista Pharmaceuticals (NASDAQ:KALV) Now Covered by JMP Securities - MarketBeat
Angioedema Pipeline 2024: Therapies Under Investigation, - openPR
KalVista Pharmaceutical's Major Talent Push: 261,000 Stock Options Awarded in Strategic Growth Move - StockTitan
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
KalVista Pharmaceuticals (NASDAQ:KALV) Upgraded by Citizens Jmp to Strong-Buy Rating - MarketBeat
Sebetralstat up for approval in Japan as on-demand HAE treatment - Angioedema News Today
KalVista Pharmaceuticals (NASDAQ:KALV) Earns Outperform Rating from Analysts at JMP Securities - Defense World
Brokerages Set KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) PT at $25.00 - Defense World
KalVista Pharmaceuticals (NASDAQ:KALV) Stock Price Passes Above 50 Day Moving AverageHere's Why - MarketBeat
Citizens Jmp Upgrades KalVista Pharmaceuticals (NASDAQ:KALV) to Strong-Buy - Defense World
JMP Securities sets $19 target for Kalvista Pharmaceuticals stock - MSN
JPMorgan Chase & Co. Raises Holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
JMP Securities Initiates Coverage of KalVista Pharmaceuticals (KALV) with Market Outperform Recommendation - MSN
JMP reiterates Kalvista stock with $19 target, sees market growth By Investing.com - Investing.com Canada
JMP Securities sets $19 target for Kalvista Pharmaceuticals stock By Investing.com - Investing.com Canada
JMP Securities Initiates KalVista Pharmaceuticals at Market Outperform With $19 Price Target - Marketscreener.com
Kalvista Pharmaceuticals Inc Stock (KALV) Financials Data
Revenue
Net Income
Cash Flow
EPS
Kalvista Pharmaceuticals Inc Stock (KALV) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Audhya Paul K. | CHIEF MEDICAL OFFICER |
Feb 18 '25 |
Sale |
9.82 |
3,125 |
30,701 |
100,334 |
| Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER |
Feb 18 '25 |
Sale |
9.82 |
5,104 |
50,143 |
278,855 |
| Venrock Healthcare Capital Par | 10% Owner |
Feb 12 '25 |
Buy |
9.23 |
100,000 |
923,000 |
5,217,285 |
| Venrock Healthcare Capital Par | 10% Owner |
Feb 13 '25 |
Buy |
9.33 |
61,700 |
575,661 |
5,278,985 |
| Venrock Healthcare Capital Par | 10% Owner |
Feb 07 '25 |
Buy |
9.29 |
73,649 |
684,199 |
5,086,445 |
| Venrock Healthcare Capital Par | 10% Owner |
Feb 11 '25 |
Buy |
9.18 |
26,703 |
245,134 |
5,117,285 |
| Venrock Healthcare Capital Par | 10% Owner |
Feb 10 '25 |
Buy |
9.14 |
4,137 |
37,812 |
5,090,582 |
| Venrock Healthcare Capital Par | 10% Owner |
Jan 30 '25 |
Buy |
8.76 |
43,707 |
382,873 |
4,986,480 |
| Venrock Healthcare Capital Par | 10% Owner |
Feb 03 '25 |
Buy |
9.22 |
14,562 |
134,262 |
5,012,796 |
| Venrock Healthcare Capital Par | 10% Owner |
Jan 31 '25 |
Buy |
8.89 |
11,754 |
104,493 |
4,998,234 |
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):